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biogenesis in Friedreich ataxia, linked to
frataxin deficiency. Martelli et al. show
that IRP1 activation in conditions of Fe-S
deficiency increases the available
cytosolic labile iron pool. Surprisingly,
this mechanism has a mitochondrial
protective role.
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Mitochondrial iron accumulation is a hallmark of dis-
eases associated with impaired iron-sulfur cluster
(Fe-S) biogenesis, such as Friedreich ataxia linked
to frataxin (FXN) deficiency. The pathophysiological
relevance of the mitochondrial iron loading and
the underlying mechanisms are unknown. Using a
mouse model of hepatic FXN deficiency in combina-
tion with mice deficient for iron regulatory protein 1
(IRP1), a key regulator of cellular iron metabolism,
we show that IRP1 activation in conditions of Fe-S
deficiency increases the available cytosolic labile
iron pool. Surprisingly, our data indicate that IRP1
activation sustains mitochondrial iron supply and
function rather than driving detrimental iron over-
load. Mitochondrial iron accumulation is shown to
depend on mitochondrial dysfunction and heme-
dependent upregulation of the mitochondrial iron
importer mitoferrin-2. Our results uncover an unex-
pected protective role of IRP1 in pathological condi-
tions associated with altered Fe-S metabolism.
INTRODUCTION
Iron-sulfur clusters (Fe-S) are essential protein cofactors in-
volved in a plethora of cellular functions (Lill, 2009). In particular,
mitochondrial function is highly dependent on Fe-S due to their
involvement in key processes such as respiration or the tricar-
boxylic acid (TCA) cycle. Inversely, Fe-S biogenesis depends
on mitochondria as de novo Fe-S assembly takes place within
thematrix (Beilschmidt and Puccio, 2014). De novo Fe-S biogen-
esis requires a scaffold protein named ISCU, on which the clus-
ter is assembled, and a cysteine desulfurase complex consisting
in NFS1 and ISD11. The Fe-S assembled on ISCU is then trans-Cell Mferred to acceptor proteins within mitochondria. Alternatively, a
compound produced by themitochondrial Fe-Smachinery is ex-
ported to the cytosol, via the ABCB7 transporter, and used as
substrate to provide Fe-S to cytosolic and nuclear acceptor pro-
teins (Lill, 2009).
Friedreich ataxia (FRDA), a progressive neurodegenerative
disease frequently involving cardiomyopathy, is the most com-
mon and emblematic disorder associated with Fe-S deficiency
(Martelli et al., 2012b). FRDA results from decreased expression
of frataxin (FXN), a mitochondrial protein that regulates the early
steps of Fe-S biogenesis through its interaction with the ISCU-
NFS1-ISD11 complex (Colin et al., 2013; Tsai and Barondeau,
2010). Characterization of conditional mouse models with FXN
deletion in heart or liver demonstrated that FXN deficiency leads
to primary Fe-S deficiency and mitochondrial dysfunction (Mar-
telli et al., 2012a; Puccio et al., 2001).
FRDA is also characterized by altered cellular iron metabolism
with mitochondrial iron accumulation (Michael et al., 2006; Puc-
cio et al., 2001). Although mitochondrial iron overload has also
been observed in other human disorders linked to Fe-S defi-
ciency (Allikmets et al., 1999; Mochel et al., 2008), its implication
in the pathophysiology of FRDA and its impact on mitochondrial
function remain elusive. Furthermore, the molecular mechanism
underlying the iron dysregulation is still unknown, although mod-
ifications in the expression of genes related to iron metabolism
were identified in the cardiac mouse model of FRDA (Martelli
and Puccio, 2014).
In mammals, cellular iron metabolism is regulated by iron
regulatory proteins (IRPs) 1 and 2 (Hentze et al., 2010). Whereas
single IRP1 or IRP2 knockout (KO) animals have a normal life
expectancy and display no overt liver phenotype (Anderson
et al., 2013; Galy et al., 2005; Ghosh et al., 2013), conditional
ablation of both IRPs in hepatocytes causes mitochondrial iron
deficiency and premature death (Galy et al., 2010), demon-
strating that the two IRPs share a redundant function in securing
mitochondrial iron needs. IRP1 and IRP2 regulate several iron-
related genes post-transcriptionally, including transferrin recep-
tor 1 (TFR1) and ferritins (FRTs), by interacting with cis-regulatoryetabolism 21, 311–322, February 3, 2015 ª2015 Elsevier Inc. 311
iron responsive elements (IREs) present in the untranslated re-
gion (UTR) of target mRNAs (Hentze et al., 2010). Formation of
IRP-IRE complexes leads to increased (e.g., TFR1) or decreased
(e.g., FRTs) protein expression depending whether the IRE is
located in the 30 or 50 UTR, respectively. In iron-replete cells,
IRP2 is regulated by proteasomal degradation mediated by
FBXL5, an iron-sensor protein that acts within an E3 ligase com-
plex (Salahudeen et al., 2009; Vashisht et al., 2009). IRP1 is pre-
dominantly regulated by reversible Fe-S binding (Hentze et al.,
2010). The Fe-S-bound form represents cytosolic aconitase
lacking IRE-binding activity and is preserved from FBXL5-medi-
ated degradation. Under normal physiological conditions, IRP1
exists mainly as an aconitase, leaving IRP2 as themain iron regu-
lator (Meyron-Holtz et al., 2004).
Early characterization in mouse and in HeLa cells showed that
IRP1 is activated into its IRE-binding form upon FXN depletion
(Seznec et al., 2005; Stehling et al., 2004). However, the implica-
tion of IRP1 in the iron dysregulation triggered by FXN deletion is
not known (Martelli and Puccio, 2014).
To determine the role of IRP1 in the phenotype associatedwith
FXN deficiency, we generated double KO mice with complete
ablation of Irp1 and liver-specific deletion of Fxn. Because the
liver copes with high amounts of iron and expresses high levels
of IRP1, this tissue is adequate to study iron metabolism dysre-
gulations and the role of IRP1 in FXN deficiency. Our study un-
covers an IRP1-dependent mechanism to sustain mitochondrial
iron needs and function in FXN deficiency. In addition, our results
challenge the widely held notion that withholding of iron from
iron-overloaded mitochondria with deficits in FXN should yield
phenotypically beneficial outcomes.
RESULTS
IRP1 Deletion Worsens the Phenotype Induced by FXN
Deficiency
Specific depletion of FXN in mouse liver (FxnAlb mice) results in
liver failure associated with mitochondrial dysfunction and
premature death starting around 28 days of age (Martelli et al.,
2012a). Further analysis of FxnAlb livers showed early impairment
of Fe-S-dependent activities such as total aconitases (ACO2 +
IRP1), succinate dehydrogenase (SDH), ferrochelatase (FECH),
and the DNA repair enzyme NTH1 at 14 days of age (Figure 1A).
Evidence of altered Fe-S biogenesis at 14 days was further pro-
vided by activation of IRP1 into its IRE-binding form, whereas
IRP2 activity (bandshift) and expression (western blotting) were
not affected (Figure 1B, left panels). At 28 days, total IRP1 protein
levels were strongly decreased in FxnAlb mice; IRP2 was below
detection both in control and deleted animals (Figure 1B, right
panels). As previously reported (Meyron-Holtz et al., 2004),
IRP1 in control mice remained mainly in its aconitase form (Fig-
ure 1B). The decreased expression of apo-IRP1 and IRP2 be-
tween 14 and 28 days most likely reflects hepatic iron loading
with age, which triggers FBXL5-mediated degradation of both
proteins. Importantly, measurement of mitochondrial iron levels
in the liver of FxnAlb mice revealed a 5-fold increase at 28 but
not 14 days of age (Figure 1C). This indicates that mitochondrial
iron accumulation in FxnAlb livers is secondary to Fe-S defi-
ciency, similar to what has been observed in the heart of mice
with cardiac Fxn deficiency (Puccio et al., 2001). Interestingly,312 Cell Metabolism 21, 311–322, February 3, 2015 ª2015 Elsevier Indespite mitochondrial iron loading, we observed no signs of pro-
tein or lipid oxidation (Figures 1D and 1E), indicating that the in-
crease in iron content does not trigger oxidative damage.
We next sought to determine the role of IRP1-IRE activation in
the context of FXN deficiency. For that purpose, we crossed
FxnAlb mice with Irp1 KO animals. As observed previously
(Martelli et al., 2012a), FXN ablation in the liver reduced life
expectancy, with most FxnAlb mice dying before 10 weeks of
age (Figure 2A). Surprisingly, IRP1 disruption exacerbated the
impact of hepatic FXN deficiency, with no Irp1;FxnAlb double
KO animal surviving beyond 5 weeks of age (Irp1;FxnAlb versus
FxnAlb; p < 0.001) (Figure 2A). This effect is specific for IRP1,
as crossing FxnAlb animals to Irp2-KO mice did not alter mouse
survival (Figure 2A).
We also evaluated hepatomegaly by measuring the liver to
body weight ratio at 23 days of age, a time point at which 80%
of Irp1;FxnAlb double KO mice were still alive. Both FxnAlb and
Irp1;FxnAlb mice displayed higher liver to body weight ratios
when compared to control and Irp1 KO animals (Figure 2B,
top). However, the hepatomegaly was significantly more pro-
nounced in double Irp1;FxnAlb than in single FxnAlb mice (note
that this is not due to differences in body weight between the
two mouse genotypes; see Figure 2B, bottom histograms).
Moreover, double Irp1;FxnAlb mice had significantly higher levels
of alanine aminotransferase (ALAT) in the plasma compared to
single FxnAlb animals (Figure 2B, bottom), as well as a tendency
for higher asparagine aminotransferase (ASAT) (Figure 2C, mid-
dle) and further reduction of albumin (Figure 2C, top), indicating a
more advanced liver dysfunction. Accordingly, genes important
for liver function such as albumin (Alb), the cytochrome P450
subunit Cyp2e1, tryptophane pyrrolase (Tdo2), and transferrin
(Tf) were more strongly suppressed in double versus single KO
mice (Figure 2D). Finally, an overall increase of stress genes
known to be stimulated in FXN deficiency (Huang et al., 2013;
Seznec et al., 2005) was observed in double Irp1;FxnAlb versus
single FxnAlb animals, with a significant upregulation of aspara-
gine synthetase (Asns) and the bifunctional methylenetetrahy-
drofolate dehydrogenase/cyclohydrolase (Mthfd2) (Figure 2E).
Together, these results demonstrate that IRP1 function/acti-
vation counteracts the liver damage associated with FXN
deficiency.
IRP1 Preserves Mitochondrial Function in FXN
Deficiency
As liver failure in FXN deficiency is associated with mitochondrial
dysfunction (Martelli et al., 2012a), we investigated the conse-
quences of IRP1 deletion on hepatic mitochondria in FxnAlb ani-
mals. Analysis by electron microscopy provided clear evidence
that the overall mitochondrial morphology and ultrastructure
was more affected in double Irp1;FxnAlb than in single FxnAlb
mice (Figure 3A). Indeed, although 23-day-old FxnAlb mice dis-
played enlarged mitochondria, loss of cristae, and curling mem-
branes in hepatocytes (Figure 3A), amore drastic phenotypewas
observed in double Irp1;FxnAlb animals, with the presence of gi-
ant mitochondria possibly resulting from mitochondrial fusion,
collapsed cristae, and electron-dense structures reminiscent of
iron deposits (Figure 3A).
We next assessed the expression of optic atrophy protein 1
(OPA1), a marker of both mitochondrial function and fusionc.
Figure 1. Biochemical Characterization of FxnAlb Mice
(A) Fe-S enzyme activities in control and FxnAlb livers (n = 3): aconitases (ACO), SDH, FECH, and NTH1. Results are given as the mean of the activity per mg of
protein ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
(B) IRP1 and IRP2 IRE-binding activities and protein levels determined by bandshift assay (EMSA), with or without adding b-mercaptoethanol (bME), and
immunoblot (IB) using liver extracts from control or FxnAlbmice. b-tubulin (bTUB) was used as loading control. p.c.: positive control corresponding to a liver protein
extract of a 14-day-old mouse.
(C) Mitochondrial iron concentration determined on mitochondrial preparations obtained with a minimum of six livers from control and FxnAlb mice. Results are
given as the mean of three independent iron measurements from the same preparation ± SD.
(D) Western blot analysis of 4-hydroxynonenal (4-HNE)-modified proteins using mitochondrial extract obtained from control and FxnAlb animals. Prohibitin (PHB)
was used as loading control.
(E) Malonaldehyde concentration determined using TBARS assay on mitochondrial preparations obtained from control and FxnAlb mice at 28 days. Results are
given as the mean of three independent measurements on the same mitochondrial preparation ± SD.(Cipolat et al., 2004; Cogliati et al., 2013). OPA1 protein levels
were increased in single FxnAlb mice and to a higher extent
in double Irp1;FxnAlb animals, indicating enhancedmitochondrial
fusion in FXN-deficient mice lacking IRP1 expression (Figure 3B).
As mitochondrial fusion is required to maintain mitochondrial
function under pathological state, our data suggest that an
increased mitochondrial fusion is required to sustain liver
function.
To further evaluate the impact of FXN and/or IRP1 depletion on
mitochondria, we assessedmRNA levels of genes of the TCA cy-Cell Mcle and respiratory chain. While mitochondrial aconitase (Aco2)
mRNA expression was increased in both single FxnAlb and dou-
ble Irp1;FxnAlb mice to the same extent, other TCA genes such as
citrate synthase (Cs) and isocitrate dehydrogenase (Idh3b sub-
unit) were upregulated in double KO animals only (Figure 3C).
Similarly, the mRNA expression of nuclear-encoded genes of
the respiratory chain (Ndufab1 of complex I, Sdhb of complex
II, and the Cox2 and Cox4 subunits of complex IV) was more
strongly upregulated in double Irp1;FxnAlb than in FxnAlb mice
(Figure 3D). These expression patterns most likely reflect aetabolism 21, 311–322, February 3, 2015 ª2015 Elsevier Inc. 313
Figure 2. Irp1 Deletion Exacerbates the FXN-Deficient Phenotype
(A) Survival curves obtained with Irp1 (n = 33), FxnAlb (n = 15), Irp1;FxnAlb (n = 33), and Irp2;FxnAlb (n = 17) mice.
(B) Liver:body weight ratio, as well as female and male body weight of control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days (n R 25). *p < 0.05, **p < 0.01,
***p < 0.001.
(C) Albumin level (nR 7), asparagine aminotransferase (ASAT), and alanine aminotransferase (ALAT) activities (n = 10) determined in blood samples of control,
FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days. *p < 0.05, **p < 0.01.
(D) mRNA levels of Alb, cytochrome P450 subunit Cyp2e1, Tdo2, or Tf determined by qRT-PCR in control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days (n = 6).
Results are given as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
(E) mRNA levels of Ddit3, Trib3, Asns, orMthfd2 determined by qRT-PCR in control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days (n = 6). Results are given as the
mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.mechanism to compensate for Fe-S deficit and the ensuing alter-
ations of the TCA cycle and respiration, which are more pro-
nounced in the absence of IRP1.
Together, our results show that activation of the IRP1 IRE-
binding form contributes to maintain mitochondrial function in
conditions of FXN deficiency.314 Cell Metabolism 21, 311–322, February 3, 2015 ª2015 Elsevier InIRP1 Activation upon Fxn Deletion Sustains
Mitochondrial Iron Supply
IRP1 is activated into its apo-, IRE-binding-form in FXN defi-
ciency (Figure 1B). As apo-IRP1 regulates IRE-containing genes
involved in iron metabolism, we tested how IRP1 depletion af-
fects their expression in FxnAlb mice. We analyzed transferrinc.
Figure 3. Irp1 Deletion Worsens the Mitochondrial Phenotype in FXN-Deficient Liver
(A) Analysis by electron microscopy of livers from control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days. m, mitochondria; L, lipid droplet; N, nucleus; cm, curled
membrane; mf, mitochondrial fusion; cc, collapse cristae; Fe, iron deposit.
(B) Western blot analysis of OPA1 protein level in control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days. b-tubulin (bTUB) was used as loading control. Right his-
togram shows the quantification of the OPA1 levels. *p < 0.05, **p < 0.01, ***p < 0.001.
(C) mRNA levels ofCs,Aco2, Idh3b, or fumarate hydratase (Fh1) determined by qRT-PCR in control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days (n = 6). Results are
given as the mean ± SD. *p < 0.05, ***p < 0.001.
(D) mRNA levels of Ndufab1 and Ndufs3 subunits of complex I (CI), Sdhb, and Sdhd subunits of complex II (CII), Uqcrfs1 subunit of complex III (CIII), Cox2 and
Cox4 subunits of complex IV (CIV), and Atp5o subunit of ATP synthase determined by qRT-PCR in control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days (n = 6).
Results are given as the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.receptor 1 (TFR1), ferroportin (FPN), and ferritin L (FRTL) proteins
involved in iron import, export, or storage, respectively. We
observed a marked increase in TFR1 protein expression in
23-day-old FxnAlb animals (Figure 4A). The rise in TFR1 was
partially blunted in double Irp1;FxnAlb mice, showing that IRP1Cell Mcontributes to the upregulation of iron import in FXN deficiency
(Figure 4A). The residual upregulation of TFR1 observed in dou-
ble Irp1;FxnAlb mice could be due to IRP2, although no differ-
ences in IRP2 protein level could be detected between double
Irp1;FxnAlb and Irp1 animals (Figure 4B). A lower Tfr1mRNA leveletabolism 21, 311–322, February 3, 2015 ª2015 Elsevier Inc. 315
Figure 4. IRP1 Activation Modifies Cellular Iron Distribution
(A) Western blot of TFR1, FPN, and FRTL in control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days. b-tubulin (bTUB) was used as loading control. Right histogram
shows quantification of TFR1 levels. *p < 0.05, ***p < 0.001.
(B) Western blot of IRP1 and IRP2 in control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days. b-tubulin (bTUB) was used as loading control.
(C) mRNA levels of Tfr1, Frtl, Frth, and Fpn determined by qRT-PCR in control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days (n = 6). Results are given as the
mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
(D) mRNA levels of total DMT1 (DMT1-tot), the IRE-containing isoform (DMT1 + IRE), or the isoform without IRE (DMT1 IRE) determined by qRT-PCR in control,
FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days (n = 6). Results are given as the mean ± SD. *p < 0.05, **p < 0.01.
(E) Western blot of FBXL5 in control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23 days. b-tubulin (bTUB) was used as loading control. Right histogram shows quan-
tification of FBXL5 levels. *p < 0.05, ***p < 0.001.
(F) Mitochondrial iron concentration determined onmitochondrial preparations obtained with aminimum of six livers from control, FxnAlb, Irp1, or Irp1;FxnAlb mice
at 23 days. Results are given as the mean of three independent iron measurements from the same preparation ± SD.
See also Figures S1 and S2.in double Irp1;FxnAlb than in single FxnAlb animals further sub-
stantiated a role of IRP1 activation in stabilizing Tfr1mRNA (Fig-
ure 4C). Of note, general liver iron conditions at 23 days were
similar to the ones observed at 28 days based on IRP1-IRE bind-
ing activity andTFR1 andFRTLprotein levels (compare Figure 1B
with S1A and Figure 4A with S1B). We further evaluated the link
between IRP1 IRE-binding activation and TFR1 upregulation in
mice deleted for Abcb7 (Abcb7Alb) and in double Irp1;Abcb7Alb
animals. ABCB7 depletion only affects cytosolic and nuclear
Fe-S cluster biogenesis, with activation of IRP1 in its IRE-binding
form (Clarke et al., 2006; Pondarre´ et al., 2006) (Figures S2A–
S2E). Contrary to FxnAlb mice, Abcb7Alb animals display no overt
liver and mitochondrial dysfunction as well as no mitochondrial
iron accumulation (Pondarre´ et al., 2006) (Figure S2F). Although
it was less pronounced than in the FxnAlb animals, a significant316 Cell Metabolism 21, 311–322, February 3, 2015 ª2015 Elsevier Inupregulation of TFR1 was measured in Abcb7Alb mice (Fig-
ure S2G). Both protein and mRNA levels were normalized
in Irp1;Abcb7Alb mice (Figures S2G and S2H), further sub-
stantiating the correlation between IRP1 activation and TFR1
upregulation.
DMT1, a divalent metal transporter involved in iron import, is
expressed as two mRNA variants, one of which contains an
IRE in its 30 UTR (Gunshin et al., 2001). We detected a slight
increase in the IRE-containing DMT1 mRNA variant in FxnAlb
mice (Figure 4D), but not in double Irp1;FxnAlb animals (Fig-
ure 4D). This result further shows that IRP1 IRE-binding activa-
tion can specifically impact on IRE-dependent protein expres-
sion in FXN-deficient mice.
FRTL levels were reduced in single FxnAlb mice as expected
with the higher IRP1 IRE-binding activity, but the decrease wasc.
not significantly reversed in the double Irp1;FxnAlb mice (Fig-
ure 4A), suggesting that IRP1 does not have a specific role
in maintaining low FRTL levels upon FXN deletion. However,
Frtl and Frth mRNA expressions were increased (Figure 4C),
possibly as a consequence of stress-mediated upregulation
(Tsuji et al., 2000; Wasserman and Fahl, 1997). Contrasting
with TFR1 and FRTL, FPN expression remained unchanged be-
tween all genotypes analyzed, suggesting that IRP1 exerts little
effect, if any, on iron export in this context (Figure 4A).
We then questioned how IRP1 activation would impact on
cytosolic iron content, and in particular on the cytosolic labile
iron pool (LIP). As classical measurement of the cytosolic iron
content cannot discriminate between iron stored in ferritin and
the LIP, we assessed the cytosolic LIP indirectly by analyzing
the iron binding protein FBXL5. Indeed, FBXL5 protein levels
reflect the size of the LIP as it is targeted to the proteasome
when not bound to iron (Salahudeen et al., 2009; Vashisht et al.,
2009) (Figure S2I). FBXL5 protein expression was significantly
increased in single FxnAlb mice at 23 days (Figure 4E), indicating
a higher cytosolic LIP than in control mice. However, FBXL5
levels were normalized in Irp1;FxnAlb mice at the same age (Fig-
ure 4E). A similar pattern was observed in single Abcb7Alb and
double Irp1;Abcb7Alb animals, respectively, confirming the link
between IRP1 activation upon Fe-S deficiency and the increase
in the cytosolic LIP (Figure S2J). Note that the differences in
iron levels between FxnAlb and Irp1;FxnAlb mice could not be
attributed to changes in systemic iron since hepcidin mRNA
expression in the liver was not significantly altered (Figure S2K).
As iron is required for mitochondrial function, we hypothesized
that the failure of FXN-deficient cells to increase the LIP when
IRP1 is missing could curtail iron supply to mitochondria and
thereby worsen the liver failure of Irp1;FxnAlb mice. We thus spe-
cifically measured the iron content of isolated mitochondria and
found that mitochondrial iron levels are indeed reduced in
Irp1;FxnAlb livers when compared to control and single KO ani-
mals (Figure 4F).
Together, our results indicate that IRP1 sustains mitochondrial
iron needs in FXN-deficient livers by increasing the available
cytosolic LIP.
IRP1 Activation Maintains Fe-S and Heme Biogenesis in
FXN Deficiency
Two main cellular processes are altered in conditions of mito-
chondrial iron depletion, as observed in Irp1;FxnAlb mice: Fe-S
biogenesis and heme biosynthesis.
We first evaluated the consequences of IRP1 deletion on Fe-
S-dependent enzymes and proteins. SDH and xanthine oxidore-
ductase (XOR) activities at 23 days were impaired to the
same extent in both FxnAlb and Irp1;FxnAlb mice (Figures S3A
and S3B). In agreement with the reported instability of proteins
devoid of their Fe-S (Guillon et al., 2009; Sheftel et al., 2012),
reduction of SDH, NDUFS3 (complex I subunit), and phosphori-
bosyl pyrophosphate amidotransferase (PPAT) protein levels
were observed in single FxnAlb and double Irp1;FxnAlb mice (Fig-
ures S3C and S3D). Among these proteins, only a slightly lower
cytosolic PPAT level in Irp1;FxnAlb mice was detected (Fig-
ure S3D). Total cellular aconitase activity (ACO2 + IRP1) was
also decreased to the same extent in single FxnAlb and double
Irp1;FxnAlb animals compared to control (Figure 5A). A close toCell M50% decrease of total aconitase activity was also observed in
Irp1 mice (Figure 5A), accounting for the proportion of cytosolic
IRP1 aconitase in the liver. Surprisingly, mitochondrial aconitase
(ACO2) levels were not decreased upon FXN depletion and were
even higher in double Irp1;FxnAlb animals (Figures S3C and S3D).
In line with the qRT-PCR results (Figure 3D), this suggests that a
compensatory mechanism is active in Fxn-deleted mice and is
more pronounced in the absence of IRP1. Of note, aconitase ac-
tivity evaluation using in-gel measurements or mitochondrial
preparations (Figures S3E and S3F) showed that FXN depletion
strongly and mainly affects IRP1 aconitase activity, thus sug-
gesting that the phenotypic difference between single FxnAlb
and double Irp1;FxnAlb KOmice is not related to the loss of cyto-
solic aconitase activity in liver.
Moreover, we tested the amount of lipoic acid (LA) bound to
the pyruvate dehydrogenase (PDH) and the a-ketoglutarate de-
hydrogenase (KGDH) complexes, which depends on the activity
of the Fe-S-containing LA synthase. Although a strong defect in
LA on PDH and on KGDH was observed in FXN-deficient mice,
no significant difference between single and double KO animals
was quantified (Figures 5B and S3G). However, the protein level
of the LA-containing E2 subunit of PDH (PDC-E2) was consis-
tently higher in Irp1;FxnAlb than in FxnAlb mice (Figures 5B and
S3G), suggesting that a molecular compensation that most likely
overcomes LA deficiency is required in the absence of IRP1.
Hence, our results show thatmost Fe-S-dependent processes
analyzed are similarly affected in single FxnAlb and double
Irp1;FxnAlb animals. However, as observed for mitochondrial
aconitase and LA bound to PDC-E2, increased compensation
seems needed in double Irp1;FxnAlb mice to obtain activities
similar to those in single KO animals. This observation may indi-
rectly reflect decreased Fe-S availability upon Irp1 deletion as a
result of mitochondrial iron depletion.
The last step of heme biogenesis requires iron insertion into
protoporphyrin IX, a reaction catalyzed by the mitochondrial
Fe-S-containing enzyme FECH. FECH activity was slightly but
significantly more impaired in Irp1;FxnAlb than in FxnAlb animals
(Figure 5C), associated with a tendency for decreased FECH
protein level (Figures S3C and S3D). FECH activity was also
lower in single Irp1 mice than in control (Figure 5C), although
FECH levels were unchanged (Figures S3C and S3D). To eval-
uate the consequence of mitochondrial iron depletion on heme
biogenesis, we assessed total heme and porphyrin contents in
the liver. In both single and double KO mice, heme and total
porphyrin levels were reduced when compared to control, but
were significantly lower in Irp1;FxnAlb than in FxnAlb animals (Fig-
ure 5D). A slightly lower amount of heme was also observed in
Irp1 mice, concomitant with a faint increase in porphyrin (Fig-
ure 5D). To test whether heme deficiency could contribute to
mitochondrial dysfunction in Irp1;FxnAlb animals, we measured
complex IV (COX) activity, a heme-dependent respiratory chain
complex. COX activity was not significantly affected among
the genotypes analyzed (Figure 5E). However, we observed a
significant increase in COX4 protein levels in double Irp1;FxnAlb
mice (Figures 5F and S3H). Altogether, less than 50% of COX4
expressed in Irp1;FxnAlb mice led to an activity (Figure 5F,
COX/COX4 ratio). Hence, these results suggest that available
heme is reduced in Irp1;FxnAlb mice compared to single KO
mice.etabolism 21, 311–322, February 3, 2015 ª2015 Elsevier Inc. 317
Figure 5. IRP1 Activation Maintains Fe-S
andHemeBiogenesis in FXN-Deficient Liver
(A) Total aconitase (ACO) activity in control, FxnAlb,
Irp1, or Irp1;FxnAlb mice at 23 days. Activities (n =
6) are given as the mean of the activity per mg of
protein ± SD. *p < 0.05, **p < 0.01, ***p < 0.001.
(B) Quantification of western blots showing LA
bound to PDC-E2 and the total amount of PDC-E2
in control, FxnAlb, Irp1, and Irp1;FxnAlb mice at
23 days (n = 6). Results are given as the mean ±
SD. See Figure S3E for western blots. *p < 0.05,
***p < 0.001.
(C) FECH activity determined in control, FxnAlb,
Irp1, and Irp1;FxnAlb mice at 23 days (n = 6).
Results are given as the mean ± SD. *p < 0.05,
**p < 0.01, ***p < 0.001.
(D) Total heme and porphyrin levels in control,
FxnAlb, Irp1, and Irp1;FxnAlb livers at 23 days (n = 6).
Results are given as the mean ± SD. *p < 0.05,
**p < 0.01, ***p < 0.001.
(E) Complex IV (COX) activity determined in con-
trol, FxnAlb, Irp1, and Irp1;FxnAlb mice at 23 days
(n = 6). Results are given as themean of the activity
per mg of protein ± SD. **p < 0.01, ***p < 0.001.
(F) Left histogram shows protein quantification of
COX4 subunit of complex IV in control, FxnAlb, Irp1,
and Irp1;FxnAlb livers at 23 days (n = 6). Left
histogram shows the relative ratio of COX activity
on COX4 protein level. Results are given as
the mean ± SD. See Figure S3F for western blot.
**p < 0.01, ***p < 0.001.
See also Figure S3.Acute Mitochondrial Iron Loading upon Fxn Deletion
Requires IRP1 Activation and MFRN2 Upregulation
While the modification of the cytosolic LIP does not induce mito-
chondrial iron accumulation in single FxnAlb animals at 23 days of
age (Figure 4F), a marked increase in mitochondrial iron levels
was observed at 28 days (Figures 1C and 6A). We hypothesized
that mitochondrial iron accumulation in FxnAlb livers depends on
MFRN2, a mitochondrial iron transporter whose mRNA expres-
sion is upregulated in the cardiac mouse model of FRDA (MCK
mice) (Huang et al., 2009) and in patients with ISCU deficiency,
a condition presenting Fe-S deficiency and mitochondrial iron
accumulation in muscle (Crooks et al., 2014). In the absence of
a specific antibody to detect the protein, we assessed Mfrn2
mRNA expression in our mouse lines at both 23 and 28 days of
age. A significant upregulation of Mfrn2 mRNA was detected in
FxnAlb animals at 28 (Figure 6B) but not at 23 days of age, sug-
gesting that mitochondrial iron accumulation is indeed related
to Mfrn2 upregulation. Interestingly, double Irp1;FxnAlb mice
exhibit high Mfrn2 mRNA expression already at 23 days of age
(Figure 6B), although mitochondrial iron levels are not increased
(Figure 4F). Meanwhile, at 28 days, double Irp1;FxnAlb mice
showed an increase in both Mfrn2 mRNA and mitochondrial
iron levels (Figures 6A and 6B). Therefore, although not sufficient,
Mfrn2 upregulation is most likely required to get a mitochondrial
iron accumulation. Accordingly, we did not detect any upregula-
tion ofMfrn2 in Abcb7Alb mice, in agreement with the absence of
mitochondrial iron accumulation (Figure S4A).318 Cell Metabolism 21, 311–322, February 3, 2015 ª2015 Elsevier InWhile FBXL5 protein expression indicates that the cytosolic
LIP is smaller in Irp1;FxnAlb than in single FxnAlb mice at
23 days of age (Figure 4E), the LIP appeared to be the same
at 28 days (Figure 6C). These data demonstrate that IRP1
depletion does not prevent but delays the capacity of FXN-defi-
cient cells to increase the cytosolic LIP. Possibly, residual
IRP1-independent upregulation of TFR1 in double KO animals
at both 23 and 28 days (Figures 4A and 6D) could mediate a
progressive increase in cytosolic iron availability. Altogether,
these results suggest that it is the concomitant activation of
IRP1 due to Fe-S deficit and the upregulation of the iron
importer MFRN2 that leads to drastic mitochondrial iron accu-
mulation in FxnAlb mice.
We next investigated the basis for Mfrn2 upregulation in FXN
deficiency. IRP1 has recently been shown to regulate the expres-
sion of HIF2-alpha (Epas1) (Anderson et al., 2013; Ghosh et al.,
2013). As Mfrn2 mRNA upregulation occurs at an earlier age
(23 days) in double Irp1;FxnAlb than in single FxnAlb animals, we
hypothesized that HIF2-alpha could trigger changes in Mfrn2
expression. However, Mfrn2 did not seem to be regulated by
either HIF2 nor HIF1 since mRNA levels remained unchanged
in mice with either loss (Epas1Alb) or gain (Hif1aAlb;VhlAlb) of
HIF2-alpha function (Figures S4B and S4C), as well as in mice
overexpressing both HIF2-alpha and HIF1-alpha (VhlAlb) (Fig-
ure S4D) (Mastrogiannaki et al., 2012). We also excluded the
implication of a general mitochondrial defect independent of
Fe-S biogenesis, as no overexpression of Mfrn2 mRNA wasc.
Figure 6. Mitochondrial Iron Accumulation
Requires IRP1 Activation and Mfrn2 Upre-
gulation
(A) Mitochondrial iron concentration determined
on mitochondrial preparations obtained with a
minimum of six livers from control, FxnAlb, Irp1, or
Irp1;FxnAlb mice at 28 days. Results are given as
themean of three independent ironmeasurements
from the same preparation ± SD.
(B) mRNA levels ofMfrn2 determined by qRT-PCR
in control, FxnAlb, Irp1, or Irp1;FxnAlb mice at 23
and 28 days (n = 6). Results are given as the
mean ± SD. **p < 0.01, ***p < 0.001.
(C) Western blot of FBXL5 in control, FxnAlb, Irp1,
or Irp1;FxnAlb mice at 28 days. b-tubulin (bTUB)
was used as loading control. Right histogram
shows quantification of FBXL5 signal. ***p < 0.001.
(D) Western blot of TFR1 and FRTL in control,
FxnAlb, Irp1, or Irp1;FxnAlb mice at 28 days.
b-tubulin (bTUB) was used as loading control.
(E) mRNA levels ofMfrn2 determined by qRT-PCR
inHmbsmice injected with saline solution (Hmbs +
NaCl), with phenobarbital (Hmbs + PB), or with
phenobarbital and heme arginate (Hmbs + PB +
HA) (n = 6). Results are given as the mean ± SD.
***p < 0.001.
See also Figure S4.detected in Cox10-deficient mice (Cox10Alb) (Figure S4E) (Diaz
et al., 2008).
As the pool of available heme was reduced earlier in double
Irp1;FxnAlb KO animals (Figures 5D–5F), we tested the role of
heme deficiency on Mfrn2 expression. For this purpose we
used Hmbs-deficient mice that display a 70% decrease in
the hepatic activity of hydroxymethylbilane synthase, a critical
enzyme of heme biosynthesis (Lindberg et al., 1996, 1999).
Intraperitoneal injection of phenobarbital (PB) in Hmbs mice
triggers an acute deficit of available heme due to induction of
p450 synthesis and the incapacity of the biosynthetic pathway
to provide a sufficient amount of heme (Homedan et al., 2014).
Interestingly, Mfrn2 mRNA expression was enhanced in PB-in-
jected animals (Figure 6E). The effect of PB on Mfrn2 was
reversed by subsequent injections of heme arginate (HA) (Fig-
ure 6E), showing that heme deficiency per se can trigger
Mfrn2 upregulation.
These results suggest thatMfrn2 upregulation in single FxnAlb
and double Irp1;FxnAlb mice results from secondary heme
deficiency.
DISCUSSION
Our study reveals that activation of IRP1 into its IRE-binding
form in FXN deficiency provides a cellular mechanism to main-
tain mitochondrial function associated with impaired Fe-S
biogenesis in liver. Stimulation of IRP1 IRE-binding activity
provides an additional pool of IRE-binding protein that supple-
ments IRP2 and has a marked effect on cellular iron import
by maintaining higher levels of TFR1. The TFR1 increase
most likely contributes to a rise of the LIP that secures iron sup-
ply to the mitochondria, preventing further damages and re-
straining compensatory mechanisms such as mitochondrial
fusion or increased expression of mitochondrial proteins. TheseCell Mcompensatory mechanisms contribute to maintain a certain
level of mitochondrial activity to overcome the Fe-S and
heme deficit. However, they are energy-demanding processes
that, in the context of impaired mitochondrial respiration and
production of ATP via the TCA cycle, could accelerate the
decline of liver function and reduce the lifespan of Irp1;FxnAlb
mice.
Quite interestingly, the iron storage and export capacity ap-
peared unaffected upon Irp1 deletion. In line with recent data
demonstrating the specific regulation of HIF2-alpha by IRP1 (An-
derson et al., 2013), we can hypothesize that IRP1 and IRP2
contribute differently to the regulation of Tfr1 mRNA turnover
due to differences in their respective affinity for the Tfr1 IRE.
Actually, it was reported that Irp1 and Irp2 deletion in liver im-
pacts differently on translation of 50 IRE-regulated genes since
Irp2 deletion mainly affects ferritin and ferroportin translation,
whereas Irp1 deletion had no significant effect on translation of
these mRNAs (Anderson et al., 2013), thus providing a potential
explanation why no effect of IRP1 activation was observed on
these proteins.
Our results also demonstrate that the characteristic mitochon-
drial iron accumulation associated with FXN deficiency is trig-
gered by the deficit in mitochondrial iron-dependent pathways.
In addition to activation of IRP1 IRE binding and the ensuing
stimulation of cellular iron import in conditions of impaired Fe-
S biogenesis, secondary heme deficiency appears as the most
likely cause of Mfrn2 upregulation, which also promotes mito-
chondrial iron loading in the liver.
The specific implication of IRP1 in increasing the cytosolic LIP
prior to the increase of mitochondrial iron import contrasts with
previous results showing that cytosolic iron is depleted as a
consequence of mitochondrial iron accumulation in FRDA cell
lines and in the cardiac FRDA (MCK) mouse model (Li et al.,
2008; Whitnall et al., 2008, 2012). These results were based onetabolism 21, 311–322, February 3, 2015 ª2015 Elsevier Inc. 319
data showing increased IRP2 levels as a marker of cytosolic iron
depletion. However, in liver, we did not observe any involvement
of IRP2, and Irp2 deletion had no effect on the lifespan of
FXN-deficient animals. These results suggest that the relative
IRP1/IRP2 ratio, which varies between cell types and tissues
(Meyron-Holtz et al., 2004), maymodulate the effect of IRP1 acti-
vation on iron metabolism. Indeed, a mouse with constitutively
active IRP1 showed that the consequences of increased IRP1
activity on iron metabolism are tissue specific (Casarrubea
et al., 2013). It would therefore be of particular interest to inves-
tigate the tissue-specific roles of IRP1 in other mouse models
of FRDA, such as in animals with cardiac or neuronal FXN
deficiency.
Together, our results provide a key element to understand the
fine-tuned regulation of mitochondrial iron metabolism in patho-
logical conditions.We show a key functional link between the Fe-
S in the holo form of IRP1 and Fe-S biogenesis: the shift between
holo- and apo-IRP1 allows the regulation of iron distribution and
availability that aims at preserving mitochondrial iron supply and
function. This regulation is most likely crucial in the pathophysi-
ology of FRDA. Although the deleterious impact of prolonged
high mitochondrial levels of iron cannot be excluded in FRDA,
our results indicate that a modification of iron distribution is
a secondary process following Fe-S deficiency that is rather
essential to preserve mitochondrial function. This indicates that
the use of iron chelation as a therapeutic approach in FRDA,
as it has been proposed (Sohn et al., 2008), should be consid-
ered with caution. In particular, the concept that mitochondrial
iron concentration should be maintained at low levels to avoid
the Fenton reaction should be reevaluated in light of our data.
Furthermore, data from FXN-deficient yeast strains showed
that iron forms aggregates and becomes unavailable for biolog-
ical processes such as heme biosynthesis (Lesuisse et al., 2003;
Seguin et al., 2011). If iron becomes biologically unavailable
within mitochondria through the formation of iron deposits, as
observed by EM in 23-day-old Irp1;FxnAlb, this may explain the
subsequent increase in iron import and further contribution to
mitochondrial iron accumulation.
EXPERIMENTAL PROCEDURES
Mice
FxnAlb, Abcb7Alb, Irp1, and Irp2 animals were obtained as described (Galy
et al., 2005; Martelli et al., 2012a; Pondarre´ et al., 2006). Irp1 and Irp2 mice
were crossed with FxnAlb or Abcb7Alb mice to generate double KO animals.
Mice were fed with a standard rodent chow (D03, SAFE, Villemoisson-sur-
Orge). All procedures were approved by the local ethical committee for Animal
Care and Use. Animals were killed by CO2 inhalation, and tissues were
collected and frozen in liquid nitrogen or processed for analysis. Histological
analysis and electron microscopy were performed as described (Martelli
et al., 2012a). Samples from Epas1Alb, VhlAlb, and VhlAlb;Hif1aAlb mice were ob-
tained as described (Mastrogiannaki et al., 2012).Cox10Alb samples were pro-
vided by F. Diaz (University of Miami). The Hmbs model displays a residual
HMBS activity of 30.9% in the liver (Lindberg et al., 1996, 1999). Hmbs mice
were injected for 3 consecutive days with PB (100 mg/kg) and the following
2 days with saline solution or heme arginate (HA, 8 mg/ml) over 8 weeks.
Mice were analyzed in C57BL/6J background.
Blood Analysis
Blood samples were collected on 4 hr fasted animals, collected in heparin-
EDTA tubes, and centrifuged at 2,300 3 g for 15 min at 4C. Plasma was
decanted and stored at 20C until use. ALAT and ASAT activities, as well320 Cell Metabolism 21, 311–322, February 3, 2015 ª2015 Elsevier Inas albumin levels, were measured with an OLYMPUS AU-400 automated lab-
oratory workstation (Olympus France SA).
Protein Extracts, Electrophoresis, and Heme and Porphyrin
Contents
Liver extraction, western blots, and IRP-IRE bandshift assay were carried out
as reported (Calmels et al., 2009; Martelli et al., 2007). Total heme and total
porphyrin (copro-, uro-, and protoporphyrin as well as 5, 6, and 7 carboxylated
derivatives) contents were assessed as reported (Delaby et al., 2008; Bozzini
et al., 2013).
Quantitative Real-Time PCR
Total RNA was extracted using Precellys24 (Bertin Technologies) and Tri Re-
agent (Molecular Research Center, Inc.) following recommendations. Reverse
transcription was achieved using Transcriptor First-Strand cDNA kit (Roche
Biosciences). Quantitative real-time PCR was performed using SYBR Green
I Master (Roche Biosciences) and Light Cycler 480 (Roche Biosciences).
Activity Measurements
Aconitases, complex II (succinate dehydrogenase), complex IV (COX), and
NTH1 activity measurements were performed as described (Martelli et al.,
2007; Puccio et al., 2001). Activities were normalized according to protein
concentration as determined by Bradford assay. In-gel XOR and aconitase
activity measurements were carried out as reported (Martelli et al., 2012a;
Tong and Rouault, 2006). Ferrochelatase activity was measured by fluoro-
metric monitoring of Zn-mesoporphyrin synthesis as described (Abitbol
et al., 2005).
Mitochondrial Preparation, Iron Content, and Malonaldehyde
Determination
Mitochondrial preparations were obtained as reported (Pallotti and Lenaz,
2007). Iron content was determined using a batophenanthroline-based spec-
trophometric approach as described (Calmels et al., 2009). Malonaldehyde
was quantified using TBARS assay as described (Seznec et al., 2005).
Statistical Analysis
Data are presented as mean ± standard deviation of the mean (SD). For statis-
tical comparison of two experimental groups, the bilateral Student’s t test was
used. p < 0.05 was considered significant. Survival curves were plotted and
analyzed using Prism software (GraphPad software).
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